$XERS News
Last published 1w ago
- 1w agoXERSXeris Biopharma Holdings, Inc. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 3w agoXERSXeris Biopharma to Report Third Quarter 2026 Financial Results and Business Highlights on November 5, 2026Business WireConference call and audio webcast to be held at 8:30 a.m. ET Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), a leading, endocrine and rare disease biopharmaceutical company committed to helping people realize better
- 4w agoXERSXeris Biopharma Reinforces Leadership in Endocrinology With Data Disclosures Spanning Commercial Portfolio and Pipeline at Multiple Scientific MeetingsBusiness WireClinical and scientific data presentations in support of Gvoke® (glucagon) injection, Recorlev® (levoketoconazole), and the investigational XP-8121 program underscore Xeris's leadership in endocrinology, including
- 1mo agoXERSXeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)Business WireXeris Biopharma Holdings, Inc. (NASDAQ:XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today
- 2mo agoXERSXP-8121 Program Overview - XERIS BIOPHARMA HOLDINGS INCEarnings Call TranscriptsHello, everyone. Thank you for joining us and welcome to Xeris Biopharma XP 8121 program overview. After today's prepared remarks, we will host a question and answer session. If you would like to ask a question, please p
- 2mo agoXERSXeris Hosts Webinar Detailing Its Comprehensive Development Program for XP-8121, an Investigational, Once-Weekly Subcutaneous Levothyroxine for HypothyroidismBusiness WireInitiation of Phase 3 registrational study on track by year-end; topline results expected in late 2028; U.S. FDA approval and launch anticipated in 2030 The Company expects XP-8121 peak net revenue potential of $1 to
- 3mo agoXERSXeris Biopharma Reports Second Quarter 2026 Financial ResultsBusiness WireTotal revenue increased to over $92 million Net product revenue increased 34% year-over-year to over $91 million Recorlev net revenue increased 81% year-over-year to approximately $57 million Tightens full-year
- 3mo agoXERSXeris Biopharma to Report Second Quarter 2026 Financial Results on August 6, 2026Business WireConference Call to be Held at 8:30 a.m. ET Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative
- 4mo agoXERSCORRECTING and REPLACING Xeris Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)Business WirePlease replace the release issued earlier today with the following corrected version that provides additional information regarding the inducement grants. The corrected release reads: XERIS ANNOUNCES INDUCEMENT
- 4mo agoXERSXeris Announces Updates to Its Board of DirectorsBusiness WireChief Executive Officer John Shannon named Chair of the Board Marla Persky to transition to Lead Independent Director of the Board Board appoints Nerissa Kreher, M.D., effective July 1, 2026 Xeris Biopharma
- 5mo agoXERSXeris Biopharma Announces Notice of Allowance From U.S. Patent and Trademark Office for New Patent Covering KEVEYIS®Business WirePatent expected to provide intellectual property protection for Keveyis through 2039 Reinforces Xeris' commitment to the primary periodic paralysis community and the patients who rely on Keveyis Xeris
- 5mo agoXERSXeris Biopharma Announces Private Exchange of Convertible NotesBusiness WireEliminates approximately $23 million of debt, resulting in approximately $2 million in annual interest savings Principal to be paid in cash, remainder in common stock Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), a
- 6mo agoXERSXeris Biopharma Reports First Quarter 2026 Financial ResultsBusiness WireTotal product revenue increased 43% year-over-year to over $82 million Recorlev net revenue increased 95% year-over-year to $50 million Tightens full-year 2026 total revenue guidance to $380 million to $390
- 6mo agoXERSXeris Biopharma to Report First Quarter 2026 Financial Results on May 7, 2026Business WireConference Call to be Held at 8:30 a.m. ET Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative
- 7mo agoXERSXeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)Business WireXeris Biopharma Holdings, Inc. (NASDAQ:XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today
- 8mo agoXERSXeris Biopharma Reports Record Performance for Fourth Quarter and Full Year 2025 and Provides Full Year 2026 GuidanceBusiness WireAchieved record quarterly and full-year total revenue of $86 million and $292 million, respectively Provides full year 2026 total revenue guidance range of $375 million to $390 million Hosts conference call and
- 8mo agoXERSXeris Biopharma Subsidiaries File Recorlev® Patent Infringement LawsuitBusiness WireFour Orange Book Listed Patents through March 2040 Orphan Drug Exclusivity through December 2028 Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), a fast-growing biopharmaceutical company committed to improving patient
- 8mo agoXERSXeris Biopharma to Report Full Year 2025 Financial Results and Provide Full Year 2026 Guidance on March 2, 2026Business WireConference Call to be Held at 8:30 a.m. ET Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative
- 10mo agoXERSXeris Expects to Deliver Record Fourth Quarter and Full-Year 2025 Total RevenueBusiness WireAnticipates full year 2025 total revenue of $292 million, exceeding the guidance range of $285-$290 million and reflecting growth of 44% compared to the prior year Expects fourth quarter and full year 2025
- 11mo agoXERSXeris Announces Notice of Allowance from U.S. Patent and Trademark Office for XP-8121 Patent ApplicationBusiness WireXeris Biopharma Holdings, Inc. (NASDAQ:XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today
- 1y agoXERSXeris Biopharma Posts Record Financial Results for the Third Quarter 2025Business WireTotal product revenue increased 40% YoY to $74 million Recorlev® revenue grew 109% YoY to $37 million Updating full-year 2025 total revenue guidance to $285-$290 million; previously $280-$290 million Hosts
- 1y agoXERSXeris Biopharma to Report Third Quarter 2025 Financial Results on November 6, 2025Business WireConference Call to be Held at 8:30 a.m. ET Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative
- 1y agoXERSXeris Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireXeris Biopharma Holdings, Inc. (NASDAQ:XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today
- 1y agoXERSAmerican Regent® Launches Gvoke VialDx™ (glucagon injection)PR NewswireAmerican Regent, Inc.® is pleased to announce the commercial launch and availability of Gvoke VialDx™ (glucagon injection). Gvoke VialDx (glucagon...
- 1y agoXERSXeris Biopharma Holdings, Inc. (XERS) Q2 2025 Earnings Call TranscriptEarnings Call Transcripts
- 1y agoXERSXeris Biopharma Reports Record Financial Results for the Second Quarter 2025 and Raises Full Year Revenue GuidanceBusiness WireTotal revenue increased 49% YoY to $71.5 million; Recorlev® revenue grew 136% YoY Raises full-year 2025 total revenue guidance to $280-$290 million from previous range of $260-$275 million Provided long-term
- 1y agoXERSXeris Biopharma to Report Second Quarter 2025 Financial Results on August 7, 2025Business WireXeris Biopharma Holdings, Inc. (NASDAQ:XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today
- 1y agoXERSXeris Unveils Strategy for Long-Term Growth and Value Creation at 2025 Analyst & Investor DayBusiness WireCompany to discuss long-range financial outlook and strategic roadmap for rapid and sustainable growth Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), a fast-growing biopharmaceutical company committed to improving
- 1y agoXERSXeris Announces Details for Analyst & Investor DayBusiness WireHybrid Event Offering In-Person or Virtual Attendance on Tuesday, June 3, 2025 Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by
- 1y agoXERSXeris Biopharma Reports Record First Quarter 2025 Financial ResultsBusiness WireTotal revenue increased 48% YoY to over $60 million Recorlev® revenue grew 141% on YoY basis Tightens full-year total revenue 2025 guidance to $260 million to $275 million Announces upcoming Investor and Analyst
- 1y agoXERSXeris Biopharma to Report First Quarter 2025 Financial Results on May 8, 2025Business WireXeris Biopharma Holdings, Inc. (NASDAQ:XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today
- 1y agoANABDSGNPSTXXERS+1Bright Peak Therapeutics Appoints John Schmid to its Board of DirectorsGlobeNewswireSAN DIEGO and BASEL, Switzerland , April 17, 2025 (GLOBE NEWSWIRE) -- Bright Peak Therapeutics, a clinical-stage biotechnology company focused on discovering and developing multifunctional immunotherapies for cancer,
- 1y agoVRNAXERSXeris Announces Changes to Its Board of DirectorsBusiness WireXeris Biopharma Holdings, Inc. (NASDAQ:XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today
- 1y agoXERSXeris Announces Approval of Supplemental New Drug Application (sNDA) of Gvoke VialDx™ (glucagon) for Use as a Diagnostic AidBusiness WireFirst concentrated, ready-to-dilute liquid glucagon available for growing procedural gastroenterology market American Regent to commercialize GVOKE VialDx™ Availability is expected in the third quarter of
- 1y agoXERSApproval of Gvoke Hypopen, Nda #212097 (Efficacy)FDA Approved DrugsApproval Date: 03/14/2025; Drug Name: Gvoke Hypopen, Nda #212097; Active Ingredients: GLUCAGON; Company: Xeris; Submission Status: Approval; Submission Classification: Efficacy; Application Number: 212097
- 1y agoXERSApproval of Gvoke Pfs, Nda #212097 (Efficacy)FDA Approved DrugsApproval Date: 03/14/2025; Drug Name: Gvoke Pfs, Nda #212097; Active Ingredients: GLUCAGON; Company: Xeris; Submission Status: Approval; Submission Classification: Efficacy; Application Number: 212097
- 1y agoXERSApproval of Gvoke Kit, Nda #212097 (Efficacy)FDA Approved DrugsApproval Date: 03/14/2025; Drug Name: Gvoke Kit, Nda #212097; Active Ingredients: GLUCAGON; Company: Xeris; Submission Status: Approval; Submission Classification: Efficacy; Application Number: 212097
- 1y agoXERSXeris Biopharma Delivers Record Fourth Quarter and Full-Year 2024 Results; and Announces 2025 GuidanceBusiness WireAchieved record quarterly and full-year total revenue of $60M and $203M, growing 35% and 24% versus prior year Recorlev® revenue more than doubled versus prior year and grew 28% in the fourth quarter
- 1y agoXERSXeris Biopharma to Report Fourth Quarter and Full-Year 2024 Financial Results on March 6, 2025Business WireConference call and webcast at 8:30am ET Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), a growth-oriented biopharmaceutical company committed to improving patients' lives by developing and commercializing innovative
- 1y agoXERSXeris Appoints Anh Nguyen, MD, MBA as Chief Medical OfficerBusiness WireKenneth Johnson, PharmD, SVP Global Development & Medical Affairs to retire Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by
- 1y agoXERSXeris to Participate in Upcoming Investor ConferencesBusiness WireXeris Biopharma Holdings, Inc. (NASDAQ:XERS), a growth-oriented biopharmaceutical company committed to improving patients' lives by developing and commercializing innovative products across a range of therapies, today
- 1y agoXERSThe American Diabetes Association and Xeris Pharmaceuticals Announce National Collaboration to Provide Life-Saving Hypoglycemia Education and AwarenessPR NewswireThe American Diabetes Association® (ADA) and Xeris Pharmaceuticals® (Xeris BioPharma Holdings, Inc.), a national supporter of the ADA, are pleased to ...
- 1y agoXERSXeris Expects to Exceed Full-Year 2024 Financial GuidanceBusiness WireFull-year 2024 total revenue projected to be $203 million, exceeding previous guidance of $198-$202 million Year-end 2024 cash position expected to be over $71 million, generating positive cash flow in the fourth
- 1y agoXERSXeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)Business WireXeris Biopharma Holdings, Inc. (NASDAQ:XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today
- 1y agoXERSXeris to Participate in Piper Sandler 36th Annual Healthcare ConferenceBusiness WireXeris Biopharma Holdings, Inc. (NASDAQ:XERS), a growth-oriented biopharmaceutical company committed to improving patients' lives by developing and commercializing innovative products across a range of therapies, today
- 2y agoXERSXeris Biopharma Holdings, Inc. (XERS) Q3 2024 Earnings Call TranscriptEarnings Call Transcripts
- 2y agoXERSXeris Biopharma Reports Third Quarter 2024 Financial ResultsBusiness WireAchieved record total revenue of $54.3M including record product revenue of $52.9M Product revenue increased 27% versus prior year and 14% over the prior quarter Ended Q3 with $69.4M in cash, cash equivalents and
- 2y agoXERSXeris Biopharma to Report Third Quarter 2024 Financial Results on November 8, 2024Business WireConference call and webcast at 8:30am ET Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), a growth-oriented biopharmaceutical company committed to improving patients' lives by developing and commercializing innovative
- 2y agoXERSXeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)Business WireXeris Biopharma Holdings, Inc. (NASDAQ:XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today
- 2y agoXERSXeris to Participate in Upcoming Investor ConferencesBusiness WireXeris Biopharma Holdings, Inc. (NASDAQ:XERS), a growth-oriented biopharmaceutical company committed to improving patients' lives by developing and commercializing innovative products across a range of therapies, today